Sign In
Buy LCTX
$1.21
-0.0700 (-5.47%)
At Close: Jul 13, 2026
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
08:00am, Monday, 13'th Jul 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogenei
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
08:00am, Monday, 06'th Jul 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf
Lineage Cell Therapeutics Q1 Earnings Call Highlights
07:11pm, Friday, 15'th May 2026
Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program i
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
09:50pm, Tuesday, 12'th May 2026
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
06:11pm, Tuesday, 12'th May 2026
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
04:01pm, Tuesday, 12'th May 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
08:00am, Tuesday, 05'th May 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
08:00am, Monday, 04'th May 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf
Lineage Announces Formation of Scientific Advisory Board
08:00am, Monday, 13'th Apr 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned
Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX
04:45am, Thursday, 26'th Mar 2026
Defender Capital LLC. bought a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the undefined quarter, according to its most recent disclosure with the Securities and Exch
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
08:00am, Tuesday, 24'th Mar 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic
Lineage Cell Therapeutics Q4 Earnings Call Highlights
01:02am, Sunday, 08'th Mar 2026
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a longer cash runway following recent warrant exercises, progress in manufacturing capabilities, and early
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
09:45pm, Thursday, 05'th Mar 2026
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
